# Golimumab in Ulcerative Colitis (UC) Patients With Loss of Response (LOR) Followed by Dose Optimization

> **NCT03182166** · PHASE2 · COMPLETED · sponsor: **Centre Hospitalier Universitaire de Saint Etienne** · enrollment: 51 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** Golimumab (Optimization)
- **DIAGNOSTIC_TEST:** Rectosigmoidoscopy
- **BIOLOGICAL:** Blood samples

## Key facts

- **NCT ID:** NCT03182166
- **Lead sponsor:** Centre Hospitalier Universitaire de Saint Etienne
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-21
- **Primary completion:** 2021-06-25
- **Final completion:** 2021-12-15
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2022-03-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03182166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03182166, "Golimumab in Ulcerative Colitis (UC) Patients With Loss of Response (LOR) Followed by Dose Optimization". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03182166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*